Tilt Biotherapeutics Signs an Agreement with Merck KGaA and Pfizer to Investigate the Dual Combination for Solid Tumors
Shots:
- Tilt initiates the collaboration with Merck KGaA & Pfizer to evaluate TILT-123 with avelumab in patients with solid tumors refractory to routine modalities
- TILT-123 will evaluate for solid tumors in the US & Europe and preclinical results of the dual combination- TILT technology and anti-PDL1 agent demonstrated immune activation & efficacy
- Bavencio (avelumab) is an anti-PD-L1 antibody act by blocking the interaction of PD-L1 with PD-1 receptors- co-develop & co-commercialize by Merck KGaA & Pfizer under the agreement signed in Nov’14. TILT-123 is an oncolytic adenovirus- replicates only in cancer cells producing immunostimulatory cytokines locally at the tumor site
Click here to read full press release/ article
Ref: Business Wire | Image: Merck KGaA
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com